Valuation : TAUNS Laboratories,Inc.

Market Cap 53.56B 349M 300M 285M 258M 484M 33.32B 486M 3.38B 1.3B 16.95B 1.31B 1.28B P/E 2026 *
10.1x
P/E 2027 * 14.9x
Enterprise Value 61.56B 401M 345M 327M 296M 556M 38.29B 559M 3.88B 1.49B 19.48B 1.51B 1.47B EV / Sales 2026
-
EV / Sales 2027 * 3.24x
Free-Float
31.24%
Yield 2026 *
7.03%
Yield 2027 * 5.58%
1 day-0.20%
1 week-0.40%
Current month-0.79%
1 month+5.68%
3 months+3.29%
6 months-7.04%
Current year-1.38%
1 week 500
Extreme 500
511
1 month 472
Extreme 472
512
Current year 463
Extreme 463
568
1 year 463
Extreme 463
577
3 years 401
Extreme 401
733
5 years 401
Extreme 401
733
10 years 401
Extreme 401
733
Manager TitleAgeSince
Chief Executive Officer 51 2014-04-30
Director of Finance/CFO 67 2018-10-31
Corporate Officer/Principal 39 2022-06-30
Director TitleAgeSince
Director/Board Member 51 2014-04-30
Director/Board Member 67 2020-08-31
Director/Board Member 53 2016-03-31
Change 5-day change 1-year change 3-year change Capi.($)
-0.20%-0.40%-9.71% - 349M
-1.04%-2.50%+177.10%+371.62% 21.13B
-1.68%-5.19%-39.31%-23.54% 9.62B
+3.33%+9.48%+425.19%+42.90% 8.94B
+1.25%-2.91%-28.85% - 6.88B
-0.14%-0.71%+82.31%+53.40% 6.54B
0.00%-6.45%-31.35%-24.13% 5.64B
-0.27%-2.60%-8.36%-20.94% 4.22B
-1.59%-9.17%+55.29%+67.99% 3.84B
-3.08%-5.58%-25.36%-32.60% 2.65B
Average -0.34%-2.62%+59.69%+54.34% 6.98B
Weighted average by Cap. -0.23%-2.01%+106.50%+132.78%

Financials

2026 2027 *
Net sales 14.76B 96.08M 82.78M 78.38M 71.05M 133M 9.18B 134M 931M 358M 4.67B 361M 353M 19.25B 125M 108M 102M 92.69M 174M 11.98B 175M 1.21B 467M 6.09B 471M 460M
Net income 5.2B 33.87M 29.18M 27.63M 25.04M 46.98M 3.24B 47.22M 328M 126M 1.65B 127M 124M 3.59B 23.39M 20.15M 19.08M 17.3M 32.45M 2.23B 32.62M 227M 87.16M 1.14B 87.85M 85.93M
Net Debt 7.99B 52.05M 44.85M 42.46M 38.49M 72.21M 4.97B 72.57M 504M 194M 2.53B 195M 191M 8.75B 57M 49.11M 46.5M 42.15M 79.08M 5.45B 79.48M 552M 212M 2.77B 214M 209M
Logo TAUNS Laboratories,Inc.
Tauns Laboratories Inc is a Japan-based company engaged in the business of developing, manufacturing and marketing in vitro diagnostic products and research reagents. The Company operates its business in the in vitro diagnostic products business segment. The Company’s main product is antigen test kit that uses immunochromatography to enable rapid diagnosis at the patient's side without the need for special equipment. The products include ImunoAce Flu, ImunoAce SARSCoV-2 II, ImunoAce SARSCoV-2 Saliva, ImunoAce SARSCoV-2/Flu, ImunoAce Adeno, ImunoAce Strep A Neo, ImunoAce hMPV, ImunoAce Mycopiasma, ImunoAce RSV Neo and ImunoAce Noro.
Employees
218
Date Price Change Volume
26-09-11 ¥502.00 -0.20% 184,000
26-09-10 ¥503.00 -0.20% 81,300
26-09-09 ¥504.00 0.00% 99,700
26-09-08 ¥504.00 -0.40% 154,000
26-09-07 ¥506.00 +0.40% 189,700
Trader
Investor
Global
Quality
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
UNDERPERFORM
Number of Analysts
2
Last Close Price
502.00JPY
Average target price
420.00JPY
Spread / Average Target
-16.33%

Annual profits - Rate of surprise

  1. Stock Market
  2. Stocks
  3. 197A Stock
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!